Complications Treatment Research

 

This resource on Type 1 Diabetes Research was created in partnership with JDRF through the JDRF – Beyond Type 1 Alliance.


 

The unfortunate truth: having Type 1 diabetes increases your risk for additional health problems. Potential complications can develop over time, and are more likely if blood glucose levels aren’t diligently managed. But significant research has gone into treating and alleviating many of the complications of diabetes.

Complications often arise due to blood vessel damage, affecting different organs such as eyes and kidneys. According to the National Institute of Health (NIH), roughly 25% of people with T1D develop retinopathy (eye disease) and 20-40% of people with T1D develop nephropathy (kidney disease).

Complications do not know Diabetes-Type, as they affect both people living with Type 1 and Type 2 — often in similar or identical ways — requiring similar or identical treatments. In order to make treatments more readily available for those with T1D as well as for those with T2D, complications research is increasingly being done with trials including both cohorts.

Complications Treatments: The Latest News

FDA Approves New Treatment for Diabetic Retinopathy


Regeneron Pharmaceuticals announced that the FDA has approved EYLEA (aflibercept) to treat all stages of diabetic retinopathy.MORE

New Evidence Shows Vital Importance of Screening For T1D in Children


By screening for Type 1 diabetes in children, Bavaria was able to decrease rates of diabetic ketoacidosis at diagnosis.MORE

Complications Treatments: Trials

Go Inside the Lab with JDRF to Learn More!

Kidney Complications: Research in Boston

A look at how JDRF is working to prevent the predictable: kidney disease for 1 in 4 people who have T1D.

Eye Complications: Research in Boston

The possible and the real need that keeps these researchers fighting to protect the vision of everyone diagnosed with T1D.

 


To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.